Study: The Superiority of Amniotic Suspension Allograft Injection for Knee Osteoarthritis Symptoms
Placental-derived tissues are a known source of anti-inflammatory and immune-modulating factors. Data on amniotic suspension allograft (ASA) for the treatment of osteoarthritis (OA) has been studied and demonstrated as safe and certain for improved pain and function.
A study conducted at New York’s Hospital for Special Surgery and 11 other leading Medical Institutions titled, “A Randomized Controlled Single-Blind Study Demonstrating Superiority of Amniotic Suspension Allograft Injection Over Hyaluronic Acid and Saline Control for Modification of Knee Osteoarthritis Symptoms,” published in the Journal of Knee Surgery, found clear evidence that amniotic suspension allograft (ASA) injections may be a superior anti-inflammatory treatment for knee osteoarthritis.
This randomized controlled trial was designed to evaluate the effects on symptoms for those treated with ASA compared with saline and hyaluronic acid (HA) in subjects with knee OA.
A total of 200 subjects were randomized 1:1:1 to ASA, HA, or saline, with subjects blinded to the allocation. This was a 3-month and 6-month study completed at the Hospital for Special Surgery (HSS).
Patients receiving ASA demonstrated significantly greater improvements from baseline for pain affecting daily-living compared with those in the HA group and with the saline groups. The subjects that were receiving ASA treatments reported less pain with mobility improvement. And fewer experienced “unacceptable” pain compared to those receiving HA and saline.
The evidence presented in this trial suggests that ASA injection is an effective treatment for nonoperative management of symptomatic knee OA.
Dr. Andreas Gomoll, M.D., a sports medicine and orthopedic surgeon at the HSS reported, “The amniotic fluid and membrane injection showed the best results because there are a lot of anti-inflammatory substances in the amniotic membrane and it is the inflammation and swelling that really hurts.” He also said, “The amniotic suspension allograft injections are also a good option for older patients as well. They allow us to try to delay or prevent altogether the need for knee replacement.”
Orca Biotech offers a ReNu®, the Amniotic Suspension Allograft from Organogenesis featured in this multicenter study.
Combining ReNu® with our patient experience tools allows providers to successfully introduce this product and seamlessly collect patient data to objectively evaluate effectiveness.
Contact us to learn how you can introduce this product into your clinical practice.
J Farr, MD, et al., “A Randomized Controlled Single-Blind Study Demonstrating Superiority of Amniotic Suspension Allograft Injection Over Hyaluronic Acid and Saline Control for Modification of Knee Osteoarthritis Symptoms.” The Journal for Knee Surgery / Vol. 32 / 11/2019